Tri Locum Partners LP Has $5.15 Million Stock Holdings in GeneDx Holdings Corp. $WGS

Key Points

• Tri Locum Partners LP reduced its holdings in GeneDx Holdings Corp. by 54.4% in Q1, owning approximately $5.15 million worth of the company at the end of the reporting period.
• GeneDx reported earnings of $0.50 per share for the last quarter, significantly surpassing expectations of $0.10, and has set FY 2025 EPS guidance.
• Analysts maintain a positive outlook on GeneDx, with several raising target prices and upgrading ratings, leading to a current consensus rating of "Moderate Buy."

Tri Locum Partners LP reduced its stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 54.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,145 shares of the company's stock after selling 69,422 shares during the period. GeneDx accounts for approximately 2.6% of Tri Locum Partners LP's holdings, making the stock its 14th biggest position. Tri Locum Partners LP owned approximately 0.21% of GeneDx worth $5,150,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in WGS. Lazard Asset Management LLC acquired a new stake in shares of GeneDx in the 4th quarter worth approximately $35,000. GAMMA Investing LLC lifted its stake in shares of GeneDx by 151.7% in the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company's stock worth $39,000 after acquiring an additional 264 shares during the period. Comerica Bank acquired a new stake in shares of GeneDx in the 4th quarter worth approximately $50,000. US Bancorp DE lifted its stake in shares of GeneDx by 3,223.5% in the 1st quarter. US Bancorp DE now owns 565 shares of the company's stock worth $50,000 after acquiring an additional 548 shares during the period. Finally, Quarry LP acquired a new stake in shares of GeneDx in the 4th quarter worth approximately $78,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a research note on Friday, May 9th. Wells Fargo & Company boosted their target price on shares of GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 30th. Guggenheim reiterated a "buy" rating and issued a $115.00 target price (up from $88.00) on shares of GeneDx in a report on Monday, June 30th. Wall Street Zen upgraded shares of GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, Piper Sandler set a $120.00 target price on shares of GeneDx and gave the stock an "overweight" rating in a report on Monday, August 4th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $101.63.

GeneDx Trading Up 0.4%

Shares of WGS stock traded up $0.49 during trading hours on Friday, reaching $129.49. 441,270 shares of the stock traded hands, compared to its average volume of 748,496. GeneDx Holdings Corp. has a 1-year low of $28.86 and a 1-year high of $130.91. The business has a fifty day moving average price of $100.03 and a 200 day moving average price of $89.62. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $3.72 billion, a PE ratio of 2,589.80 and a beta of 2.02.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The business had revenue of $102.69 million for the quarter, compared to analyst estimates of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Insider Activity

In other news, Director Jason Ryan sold 38,072 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total transaction of $4,846,565.60. Following the sale, the director owned 103,284 shares in the company, valued at $13,148,053.20. The trade was a 26.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Katherine Stueland sold 2,154 shares of the business's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $105.31, for a total transaction of $226,837.74. Following the sale, the chief executive officer owned 3,440 shares in the company, valued at $362,266.40. This represents a 38.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 561,633 shares of company stock worth $67,530,714 over the last three months. 29.60% of the stock is owned by insiders.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.